Sania Therapeutics has officially launched with a focus on developing genetic medicines to address neural circuit dysfunction. The company unveiled its suite of proprietary patented platforms at the American Society of Gene & Cell Therapy (ASGCT) conference.
Sania Therapeutics takes a human-centric approach by combining the use of adeno-associated viruses (AAV) in human neural circuits with conditionally-activated ion channels. This unique combination allows for precise and effective correction of dysfunctional neural excitation, offering potential treatments for a wide range of neurological and psychiatric disorders beyond neurology itself.
The foundational technology platforms of Sania Therapeutics were initially developed by its co-founders at University College London. The launch follows a successful Series Seed financing round, which has enabled platform development and the advancement of a lead program targeting motor disorders. Additionally, Sania Therapeutics has initiated undisclosed programs that leverage the capabilities of their platforms.
Dr. Andy Murray, the CEO & Co-Founder of Sania Therapeutics, expressed the company's vision to be at the forefront of developing medicines that selectively treat disorders of neural circuits. He highlighted the excitement in demonstrating proof-of-principle data and introducing their platforms. Dr. Jane Hughes, a member of the Advisory Board, shared her enthusiasm for Sania's innovative approach to neural modulation and its potential to benefit patients.
Sania Therapeutics is showcasing its core patented technology platforms and presenting proof-of-principle data at the ASGCT conference. The platforms enable precise delivery of proteins for neuromodulation to specific neural circuits. The R-Scan platform utilizes microfluidics and a diverse population of human induced pluripotent stem cells to recreate human neural circuits in vitro, allowing for the evolution of human-centric AAVs. The Gre-Scan platform, on the other hand, is a proprietary technology designed for high-throughput screening of gene regulatory elements.
The company's Neu-Scan platform facilitates tuneable genetic neuromodulation by testing and validating the overexpression of conditionally-activated ion channels. The proof-of-concept data being presented demonstrate the platform's ability to identify AAV-deliverable ion channels that can potentially treat dysfunctional neural excitation.
